PMID- 28237991
OWN - NLM
STAT- MEDLINE
DCOM- 20180116
LR  - 20211204
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 45
IP  - 4
DP  - 2017
TI  - Rapamycin Enhances Repressed Autophagy and Attenuates Aggressive Progression in a 
      Rat Model of IgA Nephropathy.
PG  - 293-300
LID - 10.1159/000456039 [doi]
AB  - BACKGROUND: IgA nephropathy (IgAN) has been considered to be the most frequent 
      form of primary glomerulonephritis that occurs worldwide with a variety of 
      factors involved in its occurrence and development. The impact of autophagy in 
      IgAN, however, remains partially unclear. This study was designed to investigate 
      the effects of rapamycin in an IgAN model. METHOD: After establishing an IgAN rat 
      model, SD rats were divided into 4 groups: control, control + rapamycin, IgAN, 
      IgAN + rapamycin. Proteinuria and the pathological changes and the level of 
      autophagy of kidney were texted. Identify the expression of phosphorylation and 
      total mammalian target of rapamycin (mTOR) and s6k1 as well as cyclin D1 in the 
      kidney of rats through Western blot and immunohistochemistry. RESULTS: With 
      rapamycin treatment, we observed a significant reduction in the progression of 
      proteinuria as well as alleviation of pathological lesions in IgAN rats. Besides, 
      autophagy was inhibited, while the mTOR/S6k1 pathway was activated and expression 
      of cyclin D1 was increased in IgAN. Rapamycin treatment increased autophagy and 
      decreased the expression of cyclin D1. CONCLUSION: These results may suggest that 
      mTOR-mediated autophagy inhibition may result in mesangial cell proliferation in 
      IgAN.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Liu, Di
AU  - Liu D
AD  - Nephrology Department, 2nd Xiangya Hospital, Central South University, Blood 
      Purification Center in 2nd Xiangya Hospital of Central South University, Key 
      Laboratory of Kidney Disease and Blood Purification in Hunan, Changsha, PR China.
FAU - Liu, Yexin
AU  - Liu Y
FAU - Chen, Guochun
AU  - Chen G
FAU - He, Liyu
AU  - He L
FAU - Tang, Chengyuan
AU  - Tang C
FAU - Wang, Chang
AU  - Wang C
FAU - Yang, Danyi
AU  - Yang D
FAU - Li, Huiqiong
AU  - Li H
FAU - Dong, Zheng
AU  - Dong Z
FAU - Liu, Hong
AU  - Liu H
LA  - eng
PT  - Journal Article
DEP - 20170225
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 0 (Ccnd1 protein, rat)
RN  - 0 (Immunosuppressive Agents)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases)
RN  - EC 2.7.11.1 (Rps6kb1 protein, rat)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Autophagy/*drug effects
MH  - Cell Proliferation/drug effects
MH  - Cyclin D1/metabolism
MH  - Disease Models, Animal
MH  - Glomerulonephritis, IGA/*drug therapy/pathology/urine
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Mesangial Cells/drug effects/*pathology/ultrastructure
MH  - Microscopy, Electron
MH  - Proteinuria/drug therapy/urine
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Ribosomal Protein S6 Kinases/metabolism
MH  - Signal Transduction/*drug effects
MH  - Sirolimus/*therapeutic use
MH  - TOR Serine-Threonine Kinases/metabolism
EDAT- 2017/02/27 06:00
MHDA- 2018/01/18 06:00
CRDT- 2017/02/27 06:00
PHST- 2016/10/17 00:00 [received]
PHST- 2017/01/08 00:00 [accepted]
PHST- 2017/02/27 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2017/02/27 06:00 [entrez]
AID - 000456039 [pii]
AID - 10.1159/000456039 [doi]
PST - ppublish
SO  - Am J Nephrol. 2017;45(4):293-300. doi: 10.1159/000456039. Epub 2017 Feb 25.